Spots Global Cancer Trial Database for bemarituzumab
Every month we try and update this database with for bemarituzumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer | NCT03343301 | Gastrointestina... Gastrointestina... Gastric Cancer | Bemarituzumab Modified FOLFOX... | 18 Years - | Five Prime Therapeutics, Inc. | |
| Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer | NCT05111626 | Gastric Cancer Gastroesophagea... | Bemarituzumab Nivolumab Chemotherapy Placebo | 18 Years - 100 Years | Amgen | |
| Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression | NCT05052801 | Gastric Cancer Gastroesophagea... | Bemarituzumab mFOLFOX6 Placebo | 18 Years - 100 Years | Amgen | |
| Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression | NCT05052801 | Gastric Cancer Gastroesophagea... | Bemarituzumab mFOLFOX6 Placebo | 18 Years - 100 Years | Amgen | |
| A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) | NCT05267470 | Squamous-Cell N... | Bemarituzumab Docetaxel Pembrolizumab Carboplatin Paclitaxel Nab-paclitaxel | 18 Years - 99 Years | Amgen | |
| A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer | NCT03694522 | Gastric Cancer | Bemarituzumab Placebo Modified FOLFOX... | 18 Years - | Five Prime Therapeutics, Inc. | |
| Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression | NCT05052801 | Gastric Cancer Gastroesophagea... | Bemarituzumab mFOLFOX6 Placebo | 18 Years - 100 Years | Amgen | |
| PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression | NCT02213289 | Adenocarcinoma | Trastuzumab ABT-806 Bemarituzumab Ramucirumab Nivolumab Standard cytoth... | 18 Years - | University of Chicago | |
| PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression | NCT02213289 | Adenocarcinoma | Trastuzumab ABT-806 Bemarituzumab Ramucirumab Nivolumab Standard cytoth... | 18 Years - | University of Chicago | |
| A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) | NCT05267470 | Squamous-Cell N... | Bemarituzumab Docetaxel Pembrolizumab Carboplatin Paclitaxel Nab-paclitaxel | 18 Years - 99 Years | Amgen | |
| A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression | NCT05325866 | Solid Tumors | Bemarituzumab | 18 Years - 99 Years | Amgen | |
| A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. | NCT05322577 | Gastric Cancer Gastroesophagea... | Bemarituzumab CAPOX SOX Nivolumab | 18 Years - 100 Years | Amgen | |
| A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer | NCT03343301 | Gastrointestina... Gastrointestina... Gastric Cancer | Bemarituzumab Modified FOLFOX... | 18 Years - | Five Prime Therapeutics, Inc. | |
| A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer | NCT03343301 | Gastrointestina... Gastrointestina... Gastric Cancer | Bemarituzumab Modified FOLFOX... | 18 Years - | Five Prime Therapeutics, Inc. | |
| A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer | NCT03694522 | Gastric Cancer | Bemarituzumab Placebo Modified FOLFOX... | 18 Years - | Five Prime Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
